Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.

Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ.

Blood Cancer J. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3.

2.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2018 Jul 19. doi: 10.1038/s41375-018-0216-8. [Epub ahead of print]

PMID:
30026573
3.

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D.

Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.

4.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
5.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

6.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2018 Jul 2. doi: 10.1038/s41375-018-0196-8. [Epub ahead of print]

PMID:
29967379
7.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8.

PMID:
29884741
8.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK.

Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

PMID:
29866475
9.

Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma.

Barrio S, DáVia M, Bruins L, Stühmer T, Steinbrunn T, Bittrich M, Einsele H, Stewart AK, Braggio E, Kortüm KM.

Methods Mol Biol. 2018;1792:117-128. doi: 10.1007/978-1-4939-7865-6_8.

PMID:
29797255
10.

Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.

Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):486-492.e1. doi: 10.1016/j.clml.2018.04.006. Epub 2018 May 4.

PMID:
29753692
11.

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.

González-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R.

Ann Hematol. 2018 Aug;97(8):1453-1462. doi: 10.1007/s00277-018-3316-7. Epub 2018 Apr 6.

PMID:
29623394
12.

The biosynthesis of 15N-labeled microcystins and the comparative MS/MS fragmentation of natural abundance and their 15N-labeled congeners using LC-MS/MS.

Stewart AK, Strangman WK, Percy A, Wright JLC.

Toxicon. 2018 Mar 15;144:91-102. doi: 10.1016/j.toxicon.2018.01.021. Epub 2018 Feb 7.

PMID:
29427567
13.

Metabolomics-Guided Discovery of Microginin Peptides from Cultures of the Cyanobacterium Microcystis aeruginosa.

Stewart AK, Ravindra R, Van Wagoner RM, Wright JLC.

J Nat Prod. 2018 Feb 23;81(2):349-355. doi: 10.1021/acs.jnatprod.7b00829. Epub 2018 Feb 6.

PMID:
29405714
14.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

PMID:
29381435
15.

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK.

J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.

PMID:
29341834
16.

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma.

Jain T, Narayanasamy H, Mikhael J, Reeder CB, Bergsagel PL, Mayo A, Stewart AK, Mookadam F, Fonseca R.

Blood Cancer J. 2017 Dec 13;7(12):642. doi: 10.1038/s41408-017-0026-7. No abstract available.

17.

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.

Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM.

Nat Commun. 2017 Dec 4;8(1):1922. doi: 10.1038/s41467-017-01890-w.

18.

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Shi CX, Kortüm KM, Zhu YX, Bruins LA, Jedlowski P, Votruba PG, Luo M, Stewart RA, Ahmann J, Braggio E, Stewart AK.

Mol Cancer Ther. 2017 Dec;16(12):2862-2870. doi: 10.1158/1535-7163.MCT-17-0130. Epub 2017 Sep 27.

PMID:
28958990
19.

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S; MMRF CoMMpass Network, Russell SJ, Stewart AK.

Blood Cancer J. 2017 Sep 22;7(9):e612. doi: 10.1038/bcj.2017.94.

20.

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.

Chang X, Xu Q, Hou Y, Li C, Xu Y, Stewart AK.

Int J Mol Sci. 2017 Sep 17;18(9). pii: E1999. doi: 10.3390/ijms18091999.

21.

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ.

Leukemia. 2018 Mar;32(3):719-728. doi: 10.1038/leu.2017.258. Epub 2017 Sep 1.

PMID:
28860655
22.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.

PMID:
28735890
23.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.

Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ.

Blood. 2017 Sep 7;130(10):1198-1204. doi: 10.1182/blood-2017-05-782961. Epub 2017 Jul 6.

PMID:
28684537
24.

Loss of FAM46C Promotes Cell Survival in Myeloma.

Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortüm KM, Luo M, Ahmann JM, Braggio E, Stewart AK.

Cancer Res. 2017 Aug 15;77(16):4317-4327. doi: 10.1158/0008-5472.CAN-16-3011. Epub 2017 Jun 15.

25.

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A.

Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.

26.

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR.

Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057.

27.

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA.

Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. Review.

28.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P.

Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.

29.

Introduction to the Symposium on Precision Medicine.

Curry TB, Matteson EL, Stewart AK.

Mayo Clin Proc. 2017 Jan;92(1):4-6. doi: 10.1016/j.mayocp.2016.10.027. No abstract available.

PMID:
28062064
30.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1. No abstract available.

31.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB.

JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. Review.

32.

Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R.

Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.

33.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec 23;6(1):25. doi: 10.1038/s41598-016-0021-4.

34.

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J.

J Clin Pharmacol. 2017 May;57(5):663-677. doi: 10.1002/jcph.850. Epub 2016 Dec 7.

PMID:
27925676
35.

IAP antagonists induce anti-tumor immunity in multiple myeloma.

Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL.

Nat Med. 2016 Dec;22(12):1411-1420. doi: 10.1038/nm.4229. Epub 2016 Nov 14.

36.

Multidisciplinary model to implement pharmacogenomics at the point of care.

Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM.

Genet Med. 2017 Apr;19(4):421-429. doi: 10.1038/gim.2016.120. Epub 2016 Sep 22.

37.

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A.

J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648.

38.

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, Dreosti LM, Lacy MQ, Fonseca R.

Blood Cancer J. 2016 Jul 29;6(7):e448. doi: 10.1038/bcj.2016.55. No abstract available.

39.

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS.

Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.

40.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P.

Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20.

41.

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK.

Blood Cancer J. 2016 Feb 26;6:e397. doi: 10.1038/bcj.2016.1.

42.

The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.

Zhang Z, Tong J, Tang X, Juan J, Cao B, Hurren R, Chen G, Taylor P, Xu X, Shi CX, Du J, Hou J, Wang G, Wu D, Stewart AK, Schimmer AD, Moran MF, Mao X.

Blood. 2016 Mar 31;127(13):1676-86. doi: 10.1182/blood-2015-07-658203. Epub 2016 Jan 29.

43.

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Rosenthal A, Luthi J, Belohlavek M, Kortüm KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK.

Blood Cancer J. 2016 Jan 15;6:e384. doi: 10.1038/bcj.2015.112.

44.

Building a Rapid Learning Health Care System for Oncology: Why CancerLinQ Collects Identifiable Health Information to Achieve Its Vision.

Shah A, Stewart AK, Kolacevski A, Michels D, Miller R.

J Clin Oncol. 2016 Mar 1;34(7):756-63. doi: 10.1200/JCO.2015.65.0598. Epub 2016 Jan 11.

PMID:
26755519
45.

A Primitive Growth Factor, NME7AB , Is Sufficient to Induce Stable Naïve State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation.

Carter MG, Smagghe BJ, Stewart AK, Rapley JA, Lynch E, Bernier KJ, Keating KW, Hatziioannou VM, Hartman EJ, Bamdad CC.

Stem Cells. 2016 Apr;34(4):847-59. doi: 10.1002/stem.2261. Epub 2016 Jan 7.

46.

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD.

Blood Cancer J. 2016 Jan 8;6:e378. doi: 10.1038/bcj.2015.96.

47.

SnapShot: Multiple Myeloma.

Braggio E, Kortüm KM, Stewart AK.

Cancer Cell. 2015 Nov 9;28(5):678-678.e1. doi: 10.1016/j.ccell.2015.10.014.

48.

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2015 Oct 12;28(4):541-542. doi: 10.1016/j.ccell.2015.09.010. Epub 2015 Oct 12. No abstract available.

49.

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

Rosenthal A, Kumar S, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK.

Br J Haematol. 2016 Jul;174(2):323-5. doi: 10.1111/bjh.13765. Epub 2015 Sep 25. No abstract available.

50.

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A.

Blood Cancer J. 2015 Aug 14;5:e338. doi: 10.1038/bcj.2015.60.

Supplemental Content

Loading ...
Support Center